This poster presents selected data from an interim analysis of an international, multi-centre, “real world”, observational study of naloxegol (a peripherally acting mu-opioid receptor antagonist) in the management of opioid-induced constipation in patients with cancer pain. The data relates to efficacy, tolerability and safety of the drug in this specific group of patients (which has been under-investigated up to this time). The study is ongoing, and the final results are expected in 2020.

OBSERVATIONAL STUDY OF NALOXEGOL FOR PATIENTS WITH CANCER PAIN DIAGNOSED WITH OPIOID INDUCED CONSTIPATION. NACASY STUDY PRELIMINARY RESULTS